[1]高景利,崔俊伟,石卓林,等.胸腔积液中微RNA-29a和腺苷脱氨酶联合检测对结核性胸膜炎的临床诊断效能[J].新乡医学院学报,2021,38(8):746-750.[doi:10.7683/xxyxyxb.2021.08.010]
　GAO Jingli,CUI Junwei,SHI Zhuolin,et al.Clinical efficacy of combined detection of microRNA-29a and adenosine deaminase in pleural effusion for the diagnosis of tuberculous pleuritis[J].Journal of Xinxiang Medical University,2021,38(8):746-750.[doi:10.7683/xxyxyxb.2021.08.010]
点击复制

胸腔积液中微RNA-29a和腺苷脱氨酶联合检测对结核性胸膜炎的临床诊断效能
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年8
页码:
746-750
栏目:
临床研究
出版日期:
2021-08-05

文章信息/Info

Title:
Clinical efficacy of combined detection of microRNA-29a and adenosine deaminase in pleural effusion for the diagnosis of tuberculous pleuritis
作者:
高景利1; 崔俊伟1; 石卓林2; 高　远1; 贾睿岐3
（1.新乡医学院第一附属医院结核科，河南　卫辉　453100；2.新乡医学院第一附属医院全科医学，河南　卫辉　453100；3.新乡医学院第一附属医院呼吸重症监护室，河南　卫辉　453100）
Author(s):
GAO Jingli1; CUI Junwei1; SHI Zhuolin2; GAO Yuan1; JIA Ruiqi3
（1.Department of Tuberculosis,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China2.Department of General Medicine,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China；3.Department of Respiratory Intensive Care Unit,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China）
关键词:
结核性胸膜炎; 胸腔积液; 微RNA-29a; 腺苷脱氨酶; 临床诊断效能
Keywords:
tuberculous pleuritispleural effusionmicroRNA-29aadenosine deaminaseclinical diagnostic efficacy
分类号:
R521.7
DOI:
10.7683/xxyxyxb.2021.08.010
文献标志码:
A
摘要:
目的　探讨胸腔积液中微RNA-29a（miR-29a）和腺苷脱氨酶（ADA）联合检测诊断结核性胸膜炎的临床效能。方法　选择2018年1月至2019年6月新乡医学院第一附属医院收治的142例胸腔积液患者为研究对象，根据原发病分为结核性胸腔积液（TPE）组（n=63例）和恶性胸腔积液（MPE）组（n=79例），TPE患者给予抗结核治疗方案治疗后根据有无胸膜增厚分为预后良好组和预后不良组。采用酶速率法检测胸腔积液中ADA水平，反转录聚合酶链反应（RT-PCR）检测胸腔积液中miR-29a的相对表达量。比较TPE组和MPE组患者胸腔积液中miR-29a和ADA表达水平，应用Spearman分析2组患者胸腔积液中miR-29a相对表达量与ADA水平的相关性，应用受试者操作特征（ROC）曲线分析胸腔积液中miR-29a、ADA单独及联合诊断TPE的临床效能；比较预后良好组和预后不良组TPE患者治疗前胸腔积液中miR-29a表达水平，使用ROC曲线分析TPE患者治疗前胸腔积液中miR-29a和ADA表达水平对治疗后出现胸膜增厚的临床诊断效能。结果　TPE组患者胸腔积液中miR-29a相对表达量和ADA表达水平均显著高于MPE组（P<0.05）。TPE组胸腔积液中miR-29a与ADA存在显著正相关性（r=0.314，P>0.05），MPE组患者胸腔积液中miR-29a与ADA无明显相关性（r= 0.234，P>0.05）。miR-29a诊断TPE的曲线下面积（AUC）为 0.903［95%置信区间（CI）：0.853~0.954］，当截断值为0.46时，敏感度和特异度分别为90.50%和79.70%；ADA诊断TPE的AUC为0.840（95%CI：0.767~0.913），当截断值为18.63 U·L-1 时，敏感度和特异度分别为 84.10%和74.70%；miR-29a联合ADA诊断TPE的AUC为 0.943，敏感度和特异度分别为94.90%和92.40%。预后不良组患者治疗前胸腔积液中miR-29a相对表达量显著高于预后良好组（P<0.05），预后不良组与预后良好组患者胸腔积液中ADA表达水平比较差异无统计学意义（P>0.05）。治疗前胸腔积液中miR-29a相对表达量诊断TPE患者治疗后出现胸膜增厚的AUC为0.832（95%CI：0.727~0.939），当截断值为0.615时，敏感度和特异度分别为 73.50%和78.60%；治疗前胸腔积液中ADA表达水平诊断TPE患者治疗后出现胸膜增厚的AUC为0.614（95%CI：0.432~0.795），当截断值为22.59 U·L-1时，敏感度和特异度分别为46.28%和52.56%。结论　胸腔积液中miR-29a联合ADA检测对结核性胸膜炎具有显著的临床诊断效能，miR-29a可作为诊断结核性胸膜炎患者抗结核治疗后出现胸膜增厚的标志物。
Abstract:
Objective　To investigate the clinical efficacy of microRNA-29a (miR-29a) combined with adenosine deaminase (ADA )in pleural effusion for the diagnosis of tuberculous pleuritis.Methods　A total of 142 patients with pleural effusion admitted to the First Affiliated Hospital of Xinxiang Medical University from January 2018 to June 2019 were selected as the research objects,they were divided into the tuberculous pleural effusion (TPE) group(n=63) and malignant pleural effusion (MPE) group (n=63) according to the primary disease,and the patients in the TPE group were divided into the good prognosis group and poor prognosis group according to the incidence of pleural thickening after anti-tuberculosis treatment.The relative expression level of miR-29a and ADA level in pleural effusion of patients between the TPE group and MPE group were compared.The correlation between the relative expression level of miR-29a and ADA level in pleural effusion of patients in the two groups was analyzed by Spearman,the clinical efficacy of single and combination of miR-29a and ADA in pleural effusion for the diagnosis of TPE was analyzed by receiver operating characteristic (ROC) curve.The relative expression level of miR-29a and ADA level in pleural effusion of TPE patients before treatment were compared between the good prognosis group and poor prognosis group.The ROC curve was used to analyze the clinical diagnostic efficacy of relative expression level of miR-29a and ADA level in pleural effusion of TPE patients before treatment for pleural thickening after treatment.Results　The relative expression level of miR-29a and ADA level in pleural effusion of patients in the TPE group were significantly higher than those in the MPE group (P<0.05).There was a significant positive correlation between miR-29a and ADA in pleural effusion of patients in the TPE group (r=0.314,P>0.05),there was no significant correlation between miR-29a and ADA in pleural effusion of patients in the MPE group (r=0.234,P>0.05).The area under the curve (AUC) of miR-29a in the diagnosis of TPE was 0.903 ［95% confidence interval (CI)：0.853-0.954］,when the cutoff value was 0.46,the sensitivity and specificity were 90.50% and 79.70%,respectively.The AUC of ADA in the diagnosis of TPE was 0.840 (95% CI：0.767-0.913),when the cutoff value was 18.63 U·L-1,the sensitivity and specificity were 84.10% and 74.70%,respectively.The AUC of miR-29a combined with ADA in the diagnosis of TPE was 0.943,the sensitivity and specificity were 94.90% and 92.40%,respectively.The relative expression level of miR-29a in pleural effusion of patients with poor prognosis was significantly higher than that of patients with good prognosis before treatment (P<0.05),there was no significant difference in the expression level of ADA between patients with poor prognosis and patients with good prognosis (P>0.05).The AUC of miR-29a in pleural effusion before treatment for diagnosing pleural thickening after treatment was 0.832 (95% CI：0.727-0.939),when the cutoff value was 0.615,the sensitivity and specificity were 73.50% and 78.60%,respectivelythe AUC of ADA in pleural effusion before treatment for diagnosing pleural thickening after treatment was 0.614 (95% CI：0.432-0.795),when the cutoff value was 22.59 U·L-1,the sensitivity and specificity were 46.28% and 52.56%,respectively.Conclusion　The clinical diagnostic efficacy of miR-29a combined with ADA for tuberculous pleurisy is significant,miR-29a can be used as a marker for pleural thickening in patients with tuberculous pleurisy after anti-tuberculosis treatment.

参考文献/References:

［1］　崔怡然,宇传华.基于全球视角下的中国结核病负担现状与趋势分析［J］.中华疾病控制杂志,2020,24(3)：258-263.
［2］　SHI J,LI P,ZHOU L,et al.Potential biomarkers for antidiastole of tuberculous and malignant pleural effusion by proteome analysis［J］.Biomark Med,2019,13(2)：123-133.
［3］　胡克,胡卫华.胸腔积液生物标志物对结核性和恶性胸腔积液的鉴别价值［J］.内科理论与实践,2020,15(1)：6-10.
［4］　LU T X,ROTHENBERG M E.MicroRNA［J］.J Allergy Clin Immunol,2018,141(4)：1202-1207.
［5］　李向欣,刘向东.miR-29a 靶向调控 PDGFb 促进肺癌细胞凋亡［J］.基因组学与应用生物学,2020,39(6)：2780-2784.
［6］　PEI Y F,LEI Y,LIU X Q.MiR-29a promotes cell proliferation and EMT in breast cancer by targeting ten eleven translocation 1［J］.Biochim Biophys Acta,2016,1862(11)：2177-2185.
［7］　ZAMANI S,SOHRABI A,HOSSEINI S M,et al.Deregulation of miR-21 and miR-29a in cervical cancer related to HPV infection［J］.Microrna,2019,8(2)：110-115.
［8］　汪学耀,张波,荆成宝.胸腔积液 ADA，ADA2 及 ACE 水平检测对结核性和恶性胸腔积液的鉴别诊断价值［J］.现代检验医学杂志,2020,35(4)：57-60.
［9］　中华人民共和国国家卫生和计划生育委员会.肺结核诊断标准WS 288-2017［S］.北京：人民卫生出版社,2017.
［10］　焦昕,刘宁.microRNA-29a在结核性与恶性胸腔积液鉴别诊断和疗效预测中的价值［J］.现代肿瘤医学,2019,27(4)：595-598.
［11］　李玲义,姚文静,张琪,等.胸部CT在良恶性胸腔积液诊断中的应用价值［J］.华南国防医学杂志,2019,33(2)：114-117.
［12］　吴迪,刘盛国,杨凯,等.胸腔积液的病因分布及临床特点［J］.广东医学,2020,41(14)：1459-1463.
［13］　贾敬周,祁敏现,巴玉峰,等.胸腔镜检联合细胞学快速现场评估在不明胸腔积液诊断中的临床研究［J］.中国临床医生杂志,2020,48(1)：69-71.
［14］　董静,贾红彦,潘丽萍,等.胸腔积液miRNA检测用于结核性胸膜炎诊断的研究进展［J］.中华结核和呼吸杂志,2020,43(8)：685-687.
［15］　HUANG L.The expression and clinical significance of B7-H3 and miR-145 in lung cancer patients with malignant pleural effusion［J］.Eur Rev Med Pharmacol Sci,2020,24(12)：6759-6766.
［16］　YANG Y,MA L,QIAO X,et al.Salivary microRNAs show potential as biomarkers for early diagnosis of malignant pleural effusion［J］.Transl Lung Cancer Res,2020,9(4)：1247-1257.
［17］　LI Y,WANG Z,LI Y,et al.MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer［J］.Oncol Lett,2017,13(5)：3896-3904.
［18］　SHARBATI J,LEWIN A,KUTA-LOHROFF B,et al.Integrated microRNA-mRNA-analysis of human monocyte derived macrophages upon Mycobacterium avium subsp hominissuis infection［J］.PLoS One,2011,6(5)：e20258.
［19］　陈雪芳,许文芳.活动期肺结核患者外周血miR-29a的表达及其临床意义［J］.中国微生态学杂志,2017,29(12):1416-1419.
［20］　刘永明,李冬冬,朱思远,等.外周血白细胞中miR-29a作为肺结核生物标志物及其诊断价值［J］.预防医学情报杂志,2015,31(10)：755-758.
［21］　文玉琪,李志惠,任欣欣,等.胸腔积液结核感染T细胞斑点检测与腺苷脱氨酶对结核性胸膜炎的诊断价值［J］.中国医刊,2021,56(7):732-735.

相似文献/References:

[1]于维霞,王玉红 郭悦鹏,杜荣,等.T细胞亚群测定鉴别结核性与癌性胸腔积液[J].新乡医学院学报,2000,17(01):032.
[2]张志强,郭磊.结核性包裹性胸膜炎形成原因探讨[J].新乡医学院学报,2005,22(01):057.
[3]张清君,张祥杰,张建国.纤维支气管镜在原因不明胸腔积液诊断中的应用[J].新乡医学院学报,2010,27(03):271.
[4]张功学,丁　凯,齐　峰,等.胸腔积液细胞块免疫组织化学检测对疑似肺癌患者的诊断价值[J].新乡医学院学报,2018,35(2):129.[doi:10.7683/xxyxyxb.2018.02.012]
　ZHANG Gong-xue,DING Kai,QI Feng,et al.Diagnostic value of pleural effusion cell block immunohistochemical examination in patients with suspected lung cancer[J].Journal of Xinxiang Medical University,2018,35(8):129.[doi:10.7683/xxyxyxb.2018.02.012]
[5]崔俊伟,王永亮,蔡瑞艳,等.中心静脉导管胸腔闭式引流联合超声引导靶位给药治疗结核性胸膜炎疗效观察[J].新乡医学院学报,2018,35(5):400.[doi:10.7683/xxyxyxb.2018.05.011]
　CUI Jun-wei,WANG Yong-liang,CAI Rui-yan,et al.Clinical effect of central venous catheter thoracic drainage combined with ultrasound guided target therapy in treating patients with tuberculous pleurisy[J].Journal of Xinxiang Medical University,2018,35(8):400.[doi:10.7683/xxyxyxb.2018.05.011]
[6]黄健,于建,李明瑛,等.环鸟苷酸腺苷酸合成酶-环鸟苷酸腺苷酸-干扰素基因刺激分子信号通路在结核性胸膜炎大鼠中的作用[J].新乡医学院学报,2023,40(4):313.[doi:10.7683/xxyxyxb.2023.04.003]
　HUANG Jian,YU Jian,LI Mingying,et al.Role of cyclic guanosine adenylate synthetase-cyclic guanosine monophosphate adenosine monophosphate-stimulator of interferon gene signal pathway in rats with tuberculous pleurisy[J].Journal of Xinxiang Medical University,2023,40(8):313.[doi:10.7683/xxyxyxb.2023.04.003]

更新日期/Last Update: 2021-08-05